Last reviewed · How we verify

NCT07241754

Predictors of Drug Resistant Epilepsy Among Pediatric Patients

Not yet recruiting Last updated 17 December 2025
What this trial tests

trial in Epilepsy in 200 participants. Not yet recruiting.

Timeline
29 December 2025
Primary endpoint
29 December 2026
1 February 2027

Quick facts

Lead sponsorAssiut University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment200
Start date29 December 2025
Primary completion29 December 2026
Estimated completion1 February 2027

Conditions studied

Sponsor

Assiut University

Who can join

Adults 1 to 18, any sex, with Epilepsy or Seizure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. This study aims to determine the main predictors of drug resistance in pediatric epilepsy by examining clinical data, EEG abnormalities, and neuroimaging results, in order to support early identification of resistant cases and improve treatment strategies . 2. Early introduction of new lines of treatment in case of refractory epilepsy as : Ketogenic diet , Rituximab and solumedrol

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Epilepsy

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07241754.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing